Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Effects of a Dietary Supplement Containing N-trans-Caffeoyltyramine (NCT) and N-trans-Feruloyltyramine (NFT) on Gastrointestinal Barrier Function
Conditions
Interventions
plant derived phenolics
Microcrystaline cellulose (MCC)
Locations
1
United States
Biofortis
Addison, Illinois, United States
Start Date
February 6, 2024
Primary Completion Date
December 20, 2024
Completion Date
February 6, 2025
Last Updated
March 8, 2024
NCT07371286
NCT07194772
NCT04979130
NCT04738058
NCT03027583
Lead Sponsor
Brightseed
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions